Combining the new breast cancer drug palbociclib with paclitaxel (Taxol) shrank tumors in nearly half of patients with estrogen-receptor (ER) positive breast cancer, according to new research from the Perelman School of Medicine at the University of Pennsylvania. Department faculty members Drs. Priti Lal and Michael Feldman are co-authors of the study that will be presented Saturday at the 2015 San Antonio Breast Cancer Symposium.
Read the Department of Communications news release.